DexCom : JDRF Study Results Show Continuous Glucose Monitoring Provides Significant Benefits in Management of Type 1 Diabetes

Sep 08, 2008 - New study data presented by the Juvenile Diabetes Research Foundation (JDRF) today at the 44th annual meeting of the European Association for the Study of Diabetes (EASD), showed the use of Continuous Glucose Monitoring (CGM) to be effective in the management of Type 1 Diabetes.

The JDRF initiated the study to help increase access to and reimbursement of this new technology, which has been heralded as one of the most significant advancements in diabetes self-management in the past decade. The 322 person, six-month, multi-center randomized trial included both pediatric and adult patients who used either insulin pumps or multiple daily injections to manage their diabetes. The study was conducted in the United States, and utilized all three commercially-available CGM systems, including the Seven(R) System -- developed by San Diego based DexCom(TM), Inc.... DexCom's Press Release -

DexCom, Joint Development Agreement with Animas Corporation

January 10, 2008 - DexCom, Inc. (NASDAQ: DXCM), a leading provider of continuous glucose monitoring systems for people with diabetes, announced that it has entered into a joint development agreement with Animas Corporation to integrate DexCom's continuous glucose monitoring (CGM) technology into Animas® insulin pumps... DexCom's Press Release-

Insulet and DexCom , Development Agreement

January 7, 2008 - Insulet Corporation (NASDAQ: PODD), the leader in wearable insulin pump technology with its OmniPod Insulin Management System, and DexCom, Inc. (NASDAQ: DXCM), a leading provider of continuous glucose monitoring systems for people with diabetes, announced they have signed a development agreement to integrate DexCom's continuous glucose monitoring technology into the wireless, handheld OmniPod System Personal Diabetes Manager (PDM). In addition to programming the patient's insulin delivery, the PDM with integrated DexCom technology will receive and display continuous glucose readings from DexCom's wearable sensor transmitter... DexCom's Press Release - Insulet's Press Release -

DexCom, FDA Approval to Calibrate Its SEVEN Continuous Glucose Monitoring System Using Any FDA Cleared Blood Glucose Meter

November 16, 2007 - DexCom, Inc. (NASDAQ: DXCM) announced that it has received Food and Drug Administration (FDA) approval to calibrate the SEVEN^TM, its seven-day continuous glucose monitoring system, using any FDA cleared blood glucose meter. With this approval, patients will be able to calibrate the system without using a connection cable. DexCom expects to launch this feature to new patients near the end of the first quarter of 2008 and upgrade existing patients during the second quarter of 2008... DexCom's Press Release -